Pancreatic cancer: from molecular signature to target therapy.
about
Challenges of Pancreatic Cancer.Imaging in pancreatic disease.KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model.Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed miceRegulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention.Prolonged complete response following gemcitabine-erlotinib combined therapy in advanced pancreatic cancerEnhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.Twist promotes angiogenesis in pancreatic cancer by targeting miR-497/VEGFA axis.Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers.Novel agents for the treatment of adenocarcinoma of the pancreas.Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.Cytotoxicity of gemcitabine enhanced by polyphenolics from Aronia melanocarpa in pancreatic cancer cell line AsPC-1.Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma.Clinical data combined with radiological imaging improves the accuracy of TNM staging of pancreatic body and tail adenocarcinoma.A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
P2860
Q28080671-AA7D73BB-D946-4CEA-8349-EFFAFA872256Q30275458-137327D6-FD0E-4E23-9708-7615B4CFC80DQ34286070-CEE771B0-CEF4-4D28-8459-F3A0BDCBF67AQ34391552-38F783F1-4851-4AFE-B234-5C2594AF269EQ35747302-58F5DCA2-5D1F-42AE-8656-E341C7BEA777Q36524171-1CD66E06-BB7E-457E-9692-CAFED83FA726Q36744817-C66A0267-B32D-4E63-979A-089B6C835D8DQ37093547-7F6718BF-B19F-4880-B251-E6BAD1779D4EQ37295501-466C1D12-7C90-46C2-920D-0DE274B86B77Q37354443-5FDB89CC-7530-483C-B23F-18942292A682Q37614590-8F99784E-2967-402E-ADBF-A7474B63E38BQ38684978-C91D0EDD-08DD-491C-BC01-A2A0911E0482Q38955438-EA156EA9-AE00-467E-BBE8-866B5924E608Q39141618-3AB96C26-1BA6-4677-96EC-560F4435E36CQ42373823-61E0B2BE-F5D4-4861-9842-8497825E96FFQ46100102-8B5624FA-6301-4FE4-A0B7-7F40DDA22D3B
P2860
Pancreatic cancer: from molecular signature to target therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pancreatic cancer: from molecular signature to target therapy.
@en
Pancreatic cancer: from molecular signature to target therapy.
@nl
type
label
Pancreatic cancer: from molecular signature to target therapy.
@en
Pancreatic cancer: from molecular signature to target therapy.
@nl
prefLabel
Pancreatic cancer: from molecular signature to target therapy.
@en
Pancreatic cancer: from molecular signature to target therapy.
@nl
P2093
P1476
Pancreatic cancer: from molecular signature to target therapy.
@en
P2093
P304
P356
10.1016/J.CRITREVONC.2008.03.003
P577
2008-04-23T00:00:00Z